SMAD4 Recombinant Monoclonal Antibody [22H12]
| Specifications | |
|---|---|
| Type: | Primary Antibody |
| Clonality: | Monoclonal |
| Clone Name: | 22H12 |
| Host: | HEK293F Cell |
| Reactivity: | Human |
| Isotype: | Rabbit IgG |
| Label: | Unconjugated |
| Additional Information | |
|---|---|
| Synonyms: | Mothers against decapentaplegic homolog 4 (MAD homolog 4) (Mothers against DPP homolog 4) (Deletion target in pancreatic carcinoma 4) (SMAD family member 4) (SMAD 4) (Smad4) (hSMAD4), SMAD4, DPC4 MADH4 |
| UniProt ID: | Q13485 |
Applications
ELISA, WB
Recommended Dilution
Recommended dilution: WB:1:500-1:2000
Immunogen
A synthesized peptide derived from human SMAD4
Purification/Format
Affinity Chromatography
Background
This gene encodes a member of the Smad family of signal transduction proteins. Smad proteins are phosphorylated and activated by transmembrane serine-threonine receptor kinases in response to transforming growth factor (TGF)-beta signaling. The product of this gene forms homomeric complexes and heteromeric complexes with other activated Smad proteins, which then accumulate in the nucleus and regulate the transcription of target genes. This protein binds to DNA and recognizes an 8-bp palindromic sequence (GTCTAGAC) called the Smad-binding element (SBE). The protein acts as a tumor suppressor and inhibits epithelial cell proliferation. It may also have an inhibitory effect on tumors by reducing angiogenesis and increasing blood vessel hyperpermeability. The encoded protein is a crucial component of the bone morphogenetic protein signaling pathway. The Smad proteins are subject to complex regulation by post-translational modifications. Mutations or deletions in this gene have been shown to result in pancreatic cancer, juvenile polyposis syndrome, and hereditary hemorrhagic telangiectasia syndrome.
Price
466,00 €
